SMS Pharmaceuticals Limited — Others, 15-05-2025: Monitoring Agency Report

SMS Pharmaceuticals has announced that Rs. 17.14 crore from its Rs. 114.30 crore preferential issue proceeds was used for capital expenditure during the quarter, funded by working capital transfer. Rs. 38.11 crore remains unutilized in a monitored bank account. Utilization is on track with no deviations or delays, and capital expenditure is expected to complete within two years. Funds earmarked for general corporate purposes are yet to be spent. The monitoring agency confirms proper and timely use of funds without material issues, ensuring investor interests are safeguarded.